Clavaseptin 500 mg palatable tablets for dogs

Šalis: Airija

kalba: anglų

Šaltinis: HPRA (Health Products Regulatory Authority)

Nusipirk tai dabar

Parsisiųsti Prekės savybės (SPC)
12-06-2017

Veiklioji medžiaga:

Amoxicillin, Clavulanic acid

Prieinama:

Vetoquinol UK Limited

ATC kodas:

QJ01CR02

INN (Tarptautinis Pavadinimas):

Amoxicillin, Clavulanic acid

Dozė:

500 mg/tablet

Vaisto forma:

Tablet

Recepto tipas:

POM: Prescription Only Medicine as defined in relevant national legislation

Farmakoterapinė grupė:

Dogs

Gydymo sritis:

amoxicillin and enzyme inhibitor

Terapinės indikacijos:

Antibacterial

Autorizacija statusas:

Authorised

Leidimo data:

2005-10-21

Prekės savybės

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clavaseptin 500 mg palatable tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablet.
Beige scored tablet that can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs:
treatment
or adjunctive treatment
of periodontal
infections caused by bacteria susceptible to amoxicillin in
combination with clavulanic acid i.e._ Pasteurella_ spp,_
Streptococcus_ spp and_ Escherichia coli_.
4.3 CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to penicillins or
other substances of the
-lactam group or to any of
the excipients.
Do not administer to gerbils, guinea pigs, hamsters, rabbits and
chinchillas.
Do not administer to horses and ruminating animals.
Do not use in animals with serious dysfunction of the kidneys
accompanied by anuria or oliguria.
Do not use in cases of known resistance to the combination of
amoxicillin and clavulanic acid.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Each tablet contains:
Active substances:
Amoxicillin (as amoxicillin trihydrate)
400
mg
Clavulanic acid (as potassium salt)
100
mg
Excipients
Brown iron oxide (E172)
0.950 mg
For the full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_9_
_/_
_0_
_5_
_/_
_2_
_0_
_1_
_6_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_3_
_4_
_8_
_7_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_
                                
                                Perskaitykite visą dokumentą
                                
                            

Ieškokite perspėjimų, susijusių su šiuo produktu